Since ADCYs participate in CREB activation, and CREB regulates the expression of MITF8, the increase in ADCY3 activity in CM patients with the TT genotype may favor proliferation of abnormal melanocytes leading to relapse or death by CM effects. Here, ADCY3 is linked to cutaneous mastocytosis.